Globally, there are approximately 130--150 million people living with hepatitis C (HCV), and the majority of these live in low- and middle-income countries (LMICs) \[[@b1],[@b2]\]. Due in part to the complexity and cost of the current algorithm for diagnosis and treatment using pegylated interferon, the majority of LMICs do not support HCV programming and as a result, without accessible and effective treatment, nearly half a million people die of HCV annually \[[@b2],[@b3]\]. However, the more effective and tolerable oral direct acting antivirals (DAAs) offer the opportunity to significantly simplify both the treatment and the diagnostic algorithm, enabling the implementation, decentralization and scale-up of HCV care in LMICs. To further simplify diagnosis and monitoring of HCV, dried blood spots (DBS) may be considered.

DBS has been used to aid in the diagnosis of a wide variety of pathogens, including assessment of antibody to viral or bacterial infections such as HIV, hepatitis B, HPV and measles virus \[[@b4],[@b5]\] and qualitative and quantitative viral load detection in HIV \[[@b6]\]. In particular, use of DBS in detecting and measuring HIV RNA has aided in decentralization for HIV services in low-resource areas and expanded the ability to perform early infant diagnosis for children at risk of vertical transmission \[[@b7]\].

DBS for detection and monitoring of HCV viral load has a number of advantages. Especially salient for resource-poor settings is the possibility of using DBS to store and transport samples to a central laboratory without having to use refrigeration or dry ice, which is necessary for serum/plasma samples (when stored at room temperature, serum/plasma must be processed within 6h of venous blood draw, necessitating transportation within that time) \[[@b8]--[@b10]\]. DBS can also be prepared using capillary blood, which obviates the need, seen in venipuncture, for centrifugation to separate blood cells from serum/plasma \[[@b11]\]. In injection drug users (IDUs), venipuncture can be complicated by the difficulty in finding an accessible vein, and thus, capillary blood from fingerprick samples may be easier to obtain \[[@b12]\]. DBS holds advantages over oral fluid sampling, which has also been used to detect HCV, as it has been shown that HCV RNA in saliva is independent of plasma viral load \[[@b13]\], and patients with low serum HCV RNA viral loads are less likely to have detectable HCV in saliva \[[@b14]\]. Other advantages of DBS over venipuncture include lower cost, minimal storage facility and transport requirements, decreased donor discomfort, and decreased risk to health care workers \[[@b10]\]. If DBS could be used for HCV RNA detection and monitoring, it would facilitate the simplification and decentralization of HCV diagnosis and monitoring \[[@b9],[@b15]\].

Today, a significant literature supports the use of DBS as an alternative to serum/plasma obtained via venipuncture for the detection of HCV antibody \[[@b16]--[@b18]\], yet the use of DBS in the detection and monitoring of HCV RNA and genotyping HCV, especially following storage at room temperature, has not been systematically reviewed \[[@b19]\]. To address the question of whether DBS can be used in the diagnosis of HCV in resource limited settings, we undertook a systematic review of use of DBS for HCV RNA detection and genotyping, examining a range of storage conditions.

Materials and Methods
=====================

Search strategy
---------------

Using a sensitive search strategy, as part of a predefined protocol (Appendix 1), we searched MEDLINE, CAB Abstracts and Web of Science (ISI Citation Index) published up to August 2013 for studies meeting our prespecified inclusion criteria. No date or geographical exclusions were applied; only English-language publications were included. Following an initial screen of abstracts by two separate reviewers, full text copies of potential eligible articles were reviewed independently by two reviewers. A title search of references was performed on articles meeting the inclusion criteria to determine potential articles for inclusion not identified during the initial database search. After all articles meeting the inclusion criteria were identified, data were abstracted by two reviewers according to prespecified categories.

Inclusion/exclusion criteria
----------------------------

We sought studies that reported on the use of DBS as a tool for monitoring and genotyping HCV RNA that included at least one of the following: the sensitivity and/or specificity of DBS in HCV RNA viral load quantification; the accuracy of DBS for genotyping HCV RNA; and the rate of degradation of HCV RNA during transport and storage at room temperature. Nine of the 73 articles met these criteria.

Data analysis
-------------

For studies measuring HCV RNA presence and quantification, studies were analysed for viral load endpoint detection, sensitivity, specificity, PPV and NPV of DBS compared to HCV RNA in whole plasma. For the question of HCV RNA deterioration at room temperature in DBS, reviewers extracted reports of the rate of deterioration and the definition of 'room temperature'. Studies determining HCV genotype were analysed for measures of genotype concordance between whole plasma and DBS, proportion of HCV RNA-positive DBS samples successfully genotyped, and genotypes observed.

Results
=======

Seventy-three titles were identified using the initial database search and taken for abstract review. Seventeen were selected for full text review. Overall, 9 met eligibility criteria for the review (See flow table in Fig.[1](#fig01){ref-type="fig"} \[[@b20]\]). Characteristics and findings of the studies included are summarized in Table[1](#tbl1){ref-type="table"} (for additional information, see a more complete table in the online appendices).
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###### 

Description of key variables in the included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References             Diagnostic question   Study site and population   DBS specimen collection method   Assay                                                                                                                                           HCV RNA+ samples sucessfully genotyped (types)   DBS VL endpoint detection limit (IU/mL)   DBS Sens/Spec (samples)   DBS PPV/NPV (samples)   Stability during storage at room temp
  ---------------------- --------------------- --------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ ----------------------------------------- ------------------------- ----------------------- --------------------------------------------------------------------------------
  Hope *et al*.\         Genotype              UK\                         Capillary blood on\              Dye Terminator Cycle Sequencing with Quick Start Kit (Beckman Coulter); CEQ 8000 genetic analysis system (Beckman Coulter); SEQMAN (DNAS-TAR)   114/117 (1, 2, 3, 4)                             --                                        --                        --                      --
  \[[@b24]\]                                   299 IDUs \> 15 years\       Whatman 903 card                                                                                                                                                                                                                                                                                                              
                                               177/299 anti-HCV+\                                                                                                                                                                                                                                                                                                                                        
                                               117/288 RNA+                                                                                                                                                                                                                                                                                                                                              

  Bennett *et al*.\      VL, stability         UK\                         50 μL whole\                     ABI 7500 (Applied Biosystems); ABI 9700 (Applied Biosystems)                                                                                    --                                               ≥150                                      100%\                     98.3%\                  no significant variation in cycle threshold over 1 year (2 DBS from 1 patient)
  \[[@b21]\]                                   80 anti-HCV+                blood on\                                                                                                                                                                                                                                                                   (57/57)/\                 (57/58)/\               
                                                                           Whatman\                                                                                                                                                                                                                                                                    95.7%\                    100%\                   
                                                                           903 cards                                                                                                                                                                                                                                                                   (22/23)                   (22/22)                 

  Santos *et al*.\       VL                    Brazil\                     Four drops\                      pCR-II-TOPO plasmid (Invitrogen)                                                                                                                --                                               --                                        98.0%\                    96.1%\                  --
  \[[@b11]\]                                   100 on Tx\                  capillary\                                                                                                                                                                                                                                                                  (99/101)/\                (99/103)/\              
                                               68 and 24 weeks\            blood on\                                                                                                                                                                                                                                                                   94.0%\                    96.9%\                  
                                               on Tx                       SS903 card                                                                                                                                                                                                                                                                  (63/67)                   (63/65)                 

  Mahfoud *et al*.\      Genotype              Lebanon\                    Capillary blood\                 LINEAR ARRAY HCV Genotyping Test (Roche); COBAS AMPLICOR\                                                                                       28/28\                                           --                                        --                        --                      --
  \[[@b25]\]                                   56 IDUs, anti-HCV+\         on SS903 card                    Analyzer (Roche)                                                                                                                                (1, 3, 4)                                                                                                                                    
                                               28 RNA+                                                                                                                                                                                                                                                                                                                                                   

  De Crignis *et al*.\   VL                    Italy\                      50 μL whole\                     Versant HCV RNA 3.0 b-DNA Assay (Siemens); QIAamp\                                                                                              --                                               2500                                      93.8%\                    100%\                   --
  \[[@b9]\]                                    13 HIV+/HCV+ adults\        blood on\                        DNA Mini kit (Qiagen);\                                                                                                                                                                                                                    (15/16)/\                 (15/15)/\               
                                               4 HIV+ adults\              Whatman\                         Quantitect SYBR Green PCR\                                                                                                                                                                                                                 100%\                     90%\                    
                                               3 HCV+ adults\              no. 3 card                       Master Mix (Qiagen); Taq polymerase (Invitrogen)                                                                                                                                                                                           (9/9)                     (9/10)                  
                                               5 HIV+/HCV−\                                                                                                                                                                                                                                                                                                                                              
                                               blood donors                                                                                                                                                                                                                                                                                                                                              

  Tuaillon *et al*.\     Genotype,\            France\                     3 drops (50 μL)\                 Cobas Ampliprep\                                                                                                                                14/14\                                           ≥178                                      96.8%(60/62)/--           --                      3-fold\
  \[[@b15]\]             VL, stability         100 anti-HCV+\              capillary\                       Total Nucleic\                                                                                                                                  (1, 2, 3, 4)                                                                                                                                 decrease\
                                               100 ant-HCV−                blood on\                        Acid Isolation 100 kit (Roche);\                                                                                                                                                                                                                                                             in RNA in\
                                                                           Whatman\                         Cobas TaqMan HCV test and\                                                                                                                                                                                                                                                                   6 days\
                                                                           903 card                         real-time PCR COBAS\                                                                                                                                                                                                                                                                         (no. of\
                                                                                                            TaqMan 48 instrument\                                                                                                                                                                                                                                                                        samples\
                                                                                                            plus COBAS Ampliprep\                                                                                                                                                                                                                                                                        not\
                                                                                                            analyzer (Roche); One Step\                                                                                                                                                                                                                                                                  reported)
                                                                                                            RT-PCR kit from Qiagen (Qiagen)                                                                                                                                                                                                                                                              

  Plamondon *et al*.\    Genotype              Guinea-Bissau\              Capillary\                       One-Step RT-PCR System\                                                                                                                         57/65\                                           --                                        --                        --                      --
  \[[@b23]\]                                   \>50 years                  blood on\                        (Roche)                                                                                                                                         (1, 2)                                                                                                                                       
                                                                           Whatman\                                                                                                                                                                                                                                                                                                                      
                                                                           no. 3 card                                                                                                                                                                                                                                                                                                                    

  Solmone *et al*.\      Genotype,\            Italy\                      50 μL EDTA\                      In-house RT-PCR                                                                                                                                 8/8\                                             ≥960                                      100%\                     100%\                   No loss of\
  \[[@b8]\]              VL, stability         39 anti-HCV+\               whole\                                                                                                                                                                           (1, 2, 3, 4)                                                                               (124/124)/\               (124/124)/\             RNA\
                                               34/39 RNA+\                 blood on\                                                                                                                                                                                                                                                                   100%\                     100%\                   positivity\
                                               16 anti-HCV−                SS903 card                                                                                                                                                                                                                                                                  (24/24)                   (24/24)                 after\
                                                                                                                                                                                                                                                                                                                                                                                                         11 months\
                                                                                                                                                                                                                                                                                                                                                                                                         (16 paired\
                                                                                                                                                                                                                                                                                                                                                                                                         samples)

  Abe &\                 Stability             Japan\                      50 μL serum\                     ABI Prism Dye Terminator\                                                                                                                       --                                               --                                        --                        --                      10-fold\
  Konomi \[[@b22]\]                            8 anti-HCV+\                on filter paper                  Cycle Sequencing Ready Reaction Kit (Perkin-Elmer)                                                                                                                                                                                                                                           reduction\
                                               4 anti-HCV−                                                                                                                                                                                                                                                                                                                                               in virus\
                                                                                                                                                                                                                                                                                                                                                                                                         yield in\
                                                                                                                                                                                                                                                                                                                                                                                                         4 weeks\
                                                                                                                                                                                                                                                                                                                                                                                                         (in 6 of 8\
                                                                                                                                                                                                                                                                                                                                                                                                         samples,\
                                                                                                                                                                                                                                                                                                                                                                                                         no samples\
                                                                                                                                                                                                                                                                                                                                                                                                         lost HCV\
                                                                                                                                                                                                                                                                                                                                                                                                         RNA\
                                                                                                                                                                                                                                                                                                                                                                                                         positivity)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study characteristics
---------------------

The selected studies were published between 1998 and 2012; all but two were published between 2007 and 2012. Two of the studies were located in the UK, two in Italy and one each in France, Lebanon, Brazil, Guinea-Bissau and Japan. Four studies reported outcomes in terms of endpoint sensitivity of HCV RNA detection using DBS when compared to plasma \[[@b8],[@b9],[@b15],[@b21]\]. Four studies provided data sufficient to calculate the sensitivity, specificity, positive predictive value and negative predictive value of DBS in HCV RNA detection against the standard of paired plasma samples \[[@b8],[@b9],[@b11],[@b21]\]; one study provided only enough information to measure sensitivity \[[@b15]\]. Four studies measured the stability of HCV RNA in DBS at room temperature \[[@b8],[@b15],[@b21],[@b22]\]. Two studies reported outcomes in terms of concordance between DBS and whole plasma in genotyping \[[@b8],[@b15]\]. Five studies reported the proportion of HCV RNA-positive samples that could be genotyped \[[@b8],[@b15],[@b23]--[@b25]\].

Sample characteristics
----------------------

The patient characteristics varied across studies. Two studies drew from a population of solely IDUs recruited by respondent-driven sampling \[[@b24],[@b25]\], another from a cross-section of individuals over 50 years of age \[[@b23]\]. One study used DBS to measure the viral load response to treatment \[[@b11]\], while the others did not specify the treatment experience.

Across the four studies assessing the stability of HCV RNA at room temperature, storage time varied between 2 days and twelve months from collection. The definition of 'room temperature' across four studies measuring stability of HCV RNA was given in two studies \[[@b21],[@b22]\], although not in two others \[[@b8],[@b15]\].

Finally, the preparation of DBS varied among the samples. Eight of the nine studies used DBS (only one used dried serum). Eight studies used capillary blood, while one used venous blood \[[@b8]\]. The studies used a variety of RNA extraction and elution methods and nucleic acid amplification assays.

DBS and HCV viral load quantification
-------------------------------------

HCV RNA was detected by DBS in 100% of HCV-positive samples with serum viral loads as low as 150--250 IU/mL \[[@b21]\], 334 IU/mL \[[@b15]\], 2500 IU/mL \[[@b9]\] and 4830--24 160 IU/mL \[[@b8]\]. Studies with paired serum and DBS samples found sensitivities to HCV RNA ranging from 93.8--100% and specificities ranging from 94.0--100% \[[@b8],[@b9],[@b11],[@b15],[@b21]\]. In one study of patients on treatment (100 patients after 4 weeks, and 68 patients after 24 weeks of pegylated interferon alfa-2b + ribavirin), sensitivity was 98%, specificity was 94.0%, PPV was 96.1% and NPV was 96.9% \[[@b11]\]. The one study that compared DBS HCV RNA concentration with paired serum HCV RNA found a strong correlation (*r*^2^ = 0.94; *P* \< 0.001) \[[@b15]\].

One study found deterioration of HCV RNA in DBS samples stored at room temperature, while two other studies evidenced far more stability. Tuaillon *et al*. found a threefold decrease in HCV RNA levels at 6 days compared to those stored at −20°C (although the definition of 'room temperature' and number of samples tested were not specified) \[[@b15]\]. One study saw no loss of HCV RNA positivity in 16 DBS samples after 11 months, although titres were not quantified to determine whether there was a decrease in RNA levels (again the definition of 'room temperature' was not specified) \[[@b8]\]. Another study using 2 DBS samples tested in duplicate saw no variation in the stability of HCV in DBS at 21°C over a 1-year period using an endpoint limit of detection of 250 IU/mL \[[@b21]\]. The one study of dried serum spots demonstrated a 10-fold reduction in virus yield in six of eight tested samples stored at 20--25°C after 4 weeks as compared with frozen samples \[[@b22]\].

DBS and HCV genotyping
----------------------

The two studies measuring concordance between genotype and subtype determined by DBS and plasma both found 100% concordance; one study had 8 paired samples \[[@b8]\], and another had 14 paired samples \[[@b15]\]. Four studies were able to successfully genotype most (114/117\[[@b24]\] and 57/65\[[@b23]\]) or all (28/28 \[[@b25]\] and 14/14 \[[@b15]\]) HCV RNA-positive DBS samples.

Discussion
==========

Overall, this review shows that DBS has potential for use in HCV RNA detection, quantification and genotyping. DBS is likely sufficient to detect and quantify HCV RNA for the purpose of HCV diagnosis. Viral load endpoint detection limits varied widely, yet the highest-powered study designed specifically to measure endpoint sensitivity found the lowest threshold of 150--250 IU/mL \[[@b21]\]. This remains higher than the threshold of 50 IU/mL for plasma samples, a difference multiple authors attribute to the limited sample collected by DBS using a standard 1-cm-diameter DBS punch size holding 50 μL and less efficient nucleic acid extraction\[[@b11],[@b21],[@b26]\]. The strong correlation between DBS HCV RNA concentration and paired serum HCV RNA provides additional evidence that the comparatively lower sensitivity of DBS to HCV RNA detection is attributable to this difference in sample amount \[[@b9],[@b15]\]. Given that most untreated patients with HCV have viral loads \>1000 IU/mL\[[@b15]\], the difference in sensitivity between DBS and serum/plasma may be more important for monitoring of patients during treatment than in initial diagnosis.

While one study found a strong correlation between HCV RNA concentration on DBS and serum viral load \[[@b15]\], every other author using DBS for viral load assumed the correlation was imprecise and relied instead on DBS for a qualitative determination of the presence or absence of HCV RNA in blood. This qualitative use does not allow for the precise evaluation of virologic response that does not reach undetectable levels \[[@b8],[@b9],[@b11],[@b21]\]. However, given that DAA-based treatment will rely less on response-guided treatment, HCV monitoring guidelines may change and decrease the importance of quantitative monitoring. In the near future, only qualitative virologic testing may be necessary to confirm infection, undetectable viral load at end of treatment, and sustained virologic response (SVR). Thus, the increasing use of DAAs may enable use of DBS for monitoring and confirmation of SVR.

False-positive findings for HCV RNA with DBS are not yet entirely explicable, although Santos \[[@b11]\] conjectures that the four such 'false-positive' DBS samples found in patients early in their treatment course (pegylated interferon alfa-2b +  ribavirin) might be attributable to the presence of HCV in B lymphocytes found in the DBS samples. This would account for the reproducibly negative results for the plasma samples of these patients even while their DBS specimens contained HCV RNA. Indeed, Stapleton *et al*. found that whole-blood-based HCV RNA detection was more sensitive than plasma-based methods and hypothesized that the difference was due to the presence of cell-associated HCV RNA in whole blood \[[@b27]\]. As cell-associated HCV RNA has been shown to persist long after spontaneous clearance or successful treatment, this may prove to be a problem for determining SVR by DBS \[[@b28]\]. However, techniques to reduce the measurement of cell-associated virus are being developed for measurement of HIV RNA using DBS, and these same techniques may be applied to HCV DBS \[[@b29]\].

The most persistent unanswered question in the literature is the stability of HCV RNA in DBS when stored at room temperature. Since the first study of this question was published fifteen years ago, only three additional studies have appeared in the peer-reviewed literature. One study found a threefold decrease in RNA within 6 days but did not report the number of samples tested \[[@b15]\]; another reported a 10-fold decrease in 6 of 8 samples within 4 weeks \[[@b22]\]; yet another found no significant quantitative degradation in two samples over the course of a year \[[@b21]\]; and the fourth reported 16 samples with no loss of qualitative RNA positivity after 11 months. Only two of the four studies actually specify the definition of 'room temperature,' and none specified humidity levels. The small aggregate number of samples and the wide discrepancy in results begs additional study of this important question. Even the most rapid of the reported rates of degradation might allow for the use of DBS for HCV RNA detection in the diagnosis (if not the management) of patients without refrigeration in settings removed from central laboratories, provided transport is available within days. Still, the rate of HCV RNA degradation will determine the need to store and transport DBS cards at −20°C soon after collection in many settings where immediate transport is not possible \[[@b19]\].

Use of DBS for HCV genotyping is extremely promising. Most studies demonstrated that DBS provided sufficient sample and good correlation for genotyping. The only study where PCR amplification was insufficient to genotype at least 97% of HCV RNA-positive DBS samples used a single, short, non-coding region and drew samples from a geographically broad section of the general population of Guinea-Bissau.

Conclusion
==========

Use of DBS may help to enable diagnosis and monitoring of HCV in resource-limited settings and facilitate decentralization of care within these settings. DBS for measurement of HCV RNA appears to be a reliable tool in qualitative determination of the presence or absence of HCV RNA in the blood, although DBS is less specific than serum or plasma due to a higher endpoint detection limit. With new oral medicines reaching the market, there may be less of a need for stringent quantification of viral load, so DBS may be useful in monitoring and confirmation of sustained virologic response. Because degradation of HCV RNA could cause positive samples to fall below limits of detection, the rate of degradation of HCV RNA when stored in DBS at ambient temperatures requires systematic study. The current literature supports the use of DBS in HCV genotyping. Further study and field validation are needed to help the scale-up of HCV care in LMICs.
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